Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
EudraCT No.: 2015-001830-12
PEITHO-2 is a prospective, multicenter, phase IV, single-armed (management) trial that has been designed to address clinically relevant unresolved issues in the management of patients with intermediate-risk pulmonary embolism (PE). Risk stratification of PE is based on validated imaging (echocardiographic or CT angiographic) and laboratory biomarker (circulating levels of cardiac troponins and natriuretic peptides) parameters and their combinations, as recommended by the 2014 ESC guidelines. The primary objective of the study is to determine whether treatment of acute intermediate-risk PE (as defined by the inclusion and exclusion criteria) with parenteral anticoagulation for at least 72 hours after diagnosis, followed by dabigatran over 6 months, is effective and safe. The secondary objective is to assess the recovery of right ventricular function over the first days of treatment, and to evaluate its importance for the 6-month prognosis of patients with intermediate-risk PE. Approximately 700 patients with acute symptomatic intermediate-risk PE will be included in 40 hospitals across Europe. The study is recruiting patients since January 2016.
PEITHO-2 Steering Committee and National Coordinators: Stavros Konstantinides, Germany (PI); Guy Meyer, France (Co-PI); Jan Beyer-Westendorf, Germany; Michael Christ, Germany; Daniel Dürschmied, Germany; Klaus Empen, Germany; Nazzareno Galiè, Italy; Matthias Held, Germany; Menno Huisman, The Netherlands; David Jiménez, Spain; Frederikus Klok, The Netherlands; Matija Kozak, Slovenia; Irene Lang, Austria; Nicolas Meneveau, France; Piotr Pruszczyk, Poland; Sebastian Schellong, Germany; Branislav Stefanovic, Serbia; Adam Torbicki, Poland; Franck Verschuren, Belgium
© 2017 European Society of Cardiology. All rights reserved